Date:Jan-5-2022					
Yo	ur Name: Shuang Dong				
Ma	nuscript Title: A single-arm	prospective study of apat	inib mesylate combined with pemetrexed in patients wi	<u>th</u>	
	advanced non-squamous non-small cell lung cancer after failure of first-line or second-line therapy				
Ma	nuscript number (if known)):			
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.		
	e following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>		
to		ension, you should declare	e <u>defined broadly</u> . For example, if your manuscript pertain e all relationships with manufacturers of antihypertensive the manuscript.		
	item #1 below, report all su e time frame for disclosure i		ed in this manuscript without time limit. For all other ite	:ms,	
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		Time frame: Since the initia	al planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone			
		Time frame: pas	t 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone			
3	Royalties or licenses	X None			

Consulting fees

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V N	
6	Payment for expert testimony	_XNone	
	testimony		
7	Support for attending	X None	
,	meetings and/or travel	^ None	
	go a.i.a, o. e. a. e.		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	V Name	
11	Stock of Stock options	XNone	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above c	onflict of interest in the fol	lowing box:
_			
	None		

Da	te:Jan-5-2022				
	ur Name:_Wuling Ou				
	Manuscript Title: A single-arm prospective study of apatinib mesylate combined with pemetrexed in patients with				
	advanced non-squamous non-small cell lung cancer after failure of first-line or second-line therapy				
M	anuscript number (if known)	:			
rel pa to rel Th ma	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply anuscript only. e author's relationships/activity/services and services and services and services and services are services and services and services and services are services are services and services are services	manuscript. "Related" mo e affected by the content necessarily indicate a bias it is preferable that you d to the author's relationsh ivities/interests should be	all relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment is. If you are in doubt about whether to list a lo so. Inips/activities/interests as they relate to the current e defined broadly. For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive		
In	edication, even if that medic item #1 below, report all su e time frame for disclosure i	pport for the work report	Specifications/Comments (e.g., if payments were made to you or to your institution)		
		needed)			
		Time frame: Since the initi	al planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone			
		-· · ·	v ac		
2	Grants or contracts from	Time frame: pas	st 36 months		
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: pas XNone	st 36 months		

Consulting fees

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
_	educational events	V	
6	Payment for expert testimony	_XNone	
	testimony		
7	Support for attending	X None	
′	meetings and/or travel	^ None	
	eege aa, e. e.a.e.		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid Stock or stock options	X None	
	Stock of Stock options	X Notic	
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fo	lowing box:
	None		

Da	te:Jan-5-2022		
Yo	ur Name: Yi Zhong		
Ma	anuscript Title: <u>A single-arm</u>	prospective study of apat	tinib mesylate combined with pemetrexed in patients with
<u>ad</u>	vanced non-squamous non-	small cell lung cancer afte	r failure of first-line or second-line therapy
Ma	anuscript number (if known)):	
rel pa to rel Th <u>ma</u> Th	ated to the content of your rties whose interests may b transparency and does not ationship/activity/interest, e following questions apply anuscript only. e author's relationships/act	manuscript. "Related" mee affected by the content necessarily indicate a bias it is preferable that you d to the author's relationshivities/interests should beension, you should declare	e defined broadly. For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive
In		· ·	ed in this manuscript without time limit. For all other items
In	item #1 below, report all su	· ·	
In	item #1 below, report all su	· ·	
In	item #1 below, report all su	Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your
In	item #1 below, report all su	Name all entities with whom you have this relationship or indicate	ed in this manuscript without time limit. For all other items
In	item #1 below, report all su	Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your
In	item #1 below, report all su	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
In	item #1 below, report all su e time frame for disclosure i	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
In	item #1 below, report all su e time frame for disclosure i All support for the present	Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
In	All support for the present manuscript (e.g., funding,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
In	All support for the present manuscript (e.g., funding, provision of study materials,	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
In	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
In	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
In	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
In	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
In	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work
In the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work
In	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initialXNone	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work
In the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiaXNone	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work
In the	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initiaXNone	Specifications/Comments (e.g., if payments were made to you or to your institution) al planning of the work

X__None

Consulting fees

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
13	financial interests	XNone	
	maneral interests		
	ase summarize the above co	onflict of interest in the fo	lowing box:

Da	te:	Jan-5-2022					
Yo	ur Name:	Xianmin	Zhu				
Ma	Manuscript Title: A single-arm prospective study of apatinib mesylate combined with pemetrexed in patients with						
				failure of first-line or second-line therapy			
Ma	nuscript n	umber (if known)	:				
rel par to	ated to the rties whose transparen	content of your interests may be cy and does not r	manuscript. "Related" me e affected by the content o	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a poso.			
	e following inuscript o		to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>			
to	the epidem	niology of hyperte		defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.			
		· · · · · ·	oport for the work reporte s the past 36 months.	ed in this manuscript without time limit. For all other iten	ns,		
			Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
			Time frame: Since the initia	l planning of the work			
1	manuscript provision o medical wr processing	for the present t (e.g., funding, f study materials, iting, article charges, etc.) nit for this item.	XNone				
2	Cuanta	antino ata fire iri	Time frame: past	36 months			
2		ontracts from (if not indicated above).	XNone				
3	Royalties o	r licenses	XNone				

Consulting fees

4

5	Payment or honoraria for lectures, presentations,	XNone	
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	XNone	
	meetings and or traver		
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other services		
13	Other financial or non-	V None	
13	financial interests	X None	
	illialiciai liiterests		
pام	ease summarize the above c	onflict of interest in the fol	lowing hox:
_			
	None		

Da	te: <u>Jan-5-2022</u>			
Yo	ur Name:Qian Cai			
Manuscript Title: A single-arm prospective study of apatinib mesylate combined with pemetrexed in patients with				
ad	vanced non-squamous non-	small cell lung cancer afte	r failure of first-line or second-line therapy	
Ma	anuscript number (if known)	<u>:</u>		
rel pa to	ated to the content of your rties whose interests may be	manuscript. "Related" me e affected by the content necessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.	
	e following questions apply nuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to		ension, you should declare	defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.	
	item #1 below, report all sup e time frame for disclosure is		ed in this manuscript without time limit. For all other iten	ıs,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)	
		Time frame: Since the initia	al planning of the work	
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone		
		Time frame: pas	t 36 months	
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone		
3	Royalties or licenses	XNone		

Consulting fees

4

5	lectures, presentations,	X None	
	speakers bureaus, manuscript writing or educational events		
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or pending	XNone	
9	Participation on a Data Safety Monitoring Board or Advisory Board	XNone	
10	Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid	_XNone	
11	Stock or stock options	XNone	
12	Receipt of equipment, materials, drugs, medical writing, gifts or other services	XNone	
13	Other financial or non- financial interests	XNone	
	ease summarize the above co	onflict of interest in the fol	lowing box:

Da	te:Jan-5-2022					
Your Name:Jing Zhang						
	Manuscript Title: A single-arm prospective study of apatinib mesylate combined with pemetrexed in patients with					
			failure of first-line or second-line therapy			
Ma	nuscript number (if known)	:				
related The ma	ated to the content of your ries whose interests may be transparency and does not entionship/activity/interest, of following questions apply muscript only. The author's relationships/activity entions apply and the epidemiology of hypertodication, even if that medicalized the epidemiology of the epidemiology of the that medicalized the epidemiology of the epidemio	manuscript. "Related" mederaffected by the content of the author's relationship in the content of the content o	ps/activities/interests as they relate to the <u>current</u> <u>defined broadly</u> . For example, if your manuscript perta all relationships with manufacturers of antihypertensiv	ins ⁄e		
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as				
		needed)				
		Time frame: Since the initia	l planning of the work			
1	All support for the present	X None				
	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.) No time limit for this item.					
	No time infinition this item.					
2	Crants or contracts from	Time frame: past	36 months			
2	Grants or contracts from any entity (if not indicated	XNone				
	in item #1 above).					
3	Royalties or licenses	V None				
5	Noyalties of ficelises	X None				

Consulting fees

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
11	group, paid or unpaid	V N	
11	Stock or stock options	XNone	
12	Receipt of equipment,	V None	
12	materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	Nana		
	None		

υa	te: <u>Jan-5-2022</u>					
	ur Name:Fengmin					
Manuscript Title: A single-arm prospective study of apatinib mesylate combined with pemetrexed in patients with						
	advanced non-squamous non-small cell lung cancer after failure of first-line or second-line therapy					
Ma	anuscript number (if known)):				
rel pa to rel Th ma	ated to the content of your rties whose interests may be transparency and does not ationship/activity/interest, e following questions apply muscript only. e author's relationships/act the epidemiology of hypertedication, even if that medication.	manuscript. "Related" mee affected by the content necessarily indicate a bias it is preferable that you do to the author's relationsh ivities/interests should be ension, you should declare action is not mentioned in poort for the work reported.	ips/activities/interests as they relate to the <u>current</u> e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive			
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)			
		Time frame: Since the initia	al planning of the work			
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone				
		Time frame: pas	t 36 months			
2	Grants or contracts from any entity (if not indicated in item #1 above).	X None				
3	Royalties or licenses	XNone				

Consulting fees

X__None

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ X None	
	in other board, society,		
	committee or advocacy		
4.4	group, paid or unpaid		
11	Stock or stock options	XNone	
12	Descint of annique ent	V	
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above co	onflict of interest in the fol	lowing box:
	None		
	NOTE		

		ICIVIJE DISCI	OSURE FORM
Date:	Jan-5-2022		
Your Name:			
Manuscript 7	Title: A single-arm	prospective study of apati	nib mesylate combined with pemetrexed in patients wit
advanced no	n-squamous non-	small cell lung cancer after	failure of first-line or second-line therapy
Manuscript I	number (if known)):	
related to th parties whos to transpare	e content of your se interests may b ncy and does not	manuscript. "Related" mea e affected by the content o	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.
The followin	•	to the author's relationshi	ps/activities/interests as they relate to the <u>current</u>
to the epide	miology of hypert		defined broadly. For example, if your manuscript pertain all relationships with manufacturers of antihypertensive the manuscript.
	•	pport for the work reporte s the past 36 months.	d in this manuscript without time limit. For all other iter
		Name all entities with	Specifications/Comments
		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1 All suppor	rt for the present	X None	

		whom you have this relationship or indicate none (add rows as needed)	(e.g., if payments were made to you or to your institution)
		Time frame: Since the initial	planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	_XNone	
	testimony		
7	Support for attending meetings and/or travel	X None	
8	Patents planned, issued or	XNone	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_ X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Receipt of equipment,	X None	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
		61. . 6.	

Please summarize the above conflict of interest in the following box:

None		

Please place an "X" next to the following statement to indicate your agreement:

Da	te:Jan-5-2022					
	ur Name:Jun Wan					
	Manuscript Title: A single-arm prospective study of apatinib mesylate combined with pemetrexed in patients with					
	advanced non-squamous non-small cell lung cancer after failure of first-line or second-line therapy					
Ma	Manuscript number (if known):					
rel pa to	ated to the content of your rties whose interests may b	manuscript. "Related" me e affected by the content necessarily indicate a bias	I relationships/activities/interests listed below that are cans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.			
	e following questions apply anuscript only.	to the author's relationsh	ips/activities/interests as they relate to the <u>current</u>			
to	-	ension, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.			
	item #1 below, report all su e time frame for disclosure i	-	ed in this manuscript without time limit. For all other items			
		Name all entities with whom you have this	Specifications/Comments (e.g., if payments were made to you or to your			
		relationship or indicate none (add rows as needed)	institution)			
		none (add rows as				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	none (add rows as needed)				
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	none (add rows as needed) Time frame: Since the initia				
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	none (add rows as needed) Time frame: Since the initiaXNone	Il planning of the work			
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	none (add rows as needed) Time frame: Since the initiaXNone Time frame: pas	Il planning of the work			
1	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	none (add rows as needed) Time frame: Since the initiaXNone	Il planning of the work			
	manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Grants or contracts from any entity (if not indicated	none (add rows as needed) Time frame: Since the initiaXNone Time frame: pas	Il planning of the work			

Consulting fees

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
-	educational events	V N	
6	Payment for expert testimony	_XNone	
	testimony		
7	Support for attending	X None	
'	meetings and/or travel	^ None	
	meetings and, or traver		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	X None	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
12	Descript of a major and	Y	
12	Receipt of equipment, materials, drugs, medical	XNone	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Ple	ease summarize the above o	onflict of interest in the fol	lowing box:
	Nege		
None			

ICIVIJE DISCLOSURE FORIVI			
Date: Jan-5-2022			
Your Name: Sheng Hu			
Manuscript Title: A single-arm prospective study of apatinib mesylate combined with pemetrexed in patients with			
advanced non-squamous non-small cell lung cancer after failure of first-line or second-line therapy			
Manuscript number (if known):			
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.			
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u> .			
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.			
In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.			

Specifications/Comments

		whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	(e.g., if payments were made to you or to your institution) planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	X None	

Name all entities with

_**X**__None

Consulting fees

4

5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert testimony	_XNone	
7	Support for attending meetings and/or travel	XNone	
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	_XNone	
	in other board, society,		
	committee or advocacy		
44	group, paid or unpaid	•	
11	Stock or stock options	XNone	
4.2		•	
12	Receipt of equipment,	XNone	
	materials, drugs, medical writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests	XNone	
Ple	ease summarize the above c	onflict of interest in the fol	lowing box:
_			
	None		